Tectonic Therapeutic Shares Hit 52-Week High
Tectonic Therapeutic Shares Hit 52-Week High After Positive Trial Data
Tectonic Therapeutic shares doubled, to $56.80, after the company said it saw positive interim data from a Phase 1b acute hemodynamic clinical trial of its lead product candidate, TX45, a long-acting, Fc-relaxin fusion protein.
Leerink Partners analyst David Risinger noted the significant concern about the likelihood of success of TX45 in PH-HFpEF ...
The discontinuation comes after the investigational drug, volenrelaxin, failed a related heart failure study in an ...
Tectonic's lead asset, TX45, is a long-acting Fc-relaxin fusion protein to treat group 2 pulmonary hypertension, showing promise in early clinical trials. TX45's extended half-life and monthly ...
Investing.com -- Shares of Tectonic plummeted 41% Tuesday following ... concerns over the future of TECX's lead product candidate, TX45, which targets the same RXFP1 receptor as Lilly's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback